
Researchers working with Professor Martin Fussenegger at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have …

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …

Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …

Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …

A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …

Ingrid Copperman recounts the many ways she has dealt with her diagnosis, as well as how the power of social …